9.10 Boston Preliminary
Date: September 10, 9:00-12:30 am
Venue: Boston Convention Center 415 Summer Street, Boston, MA, 02210
What you can get?
- 1-to-1 partnering opportunities with potential Chinese investors.
- Media coverage and promotion on our English and Chinese platforms.
- Opportunity for a 5-day sponsored business development trip in China to meet 100+ investors and corporate executives.
Jointechlabs, Inc. is a biotech company co-founded in 2013 by three professionals with focus on regenerative medicine. Our initial product is Mini-Stem™, a disposable closed-loop medical device for point-of-care processing of adipose tissue for both – fat grafts and stem-cell fractions. FDA device approval for Mini-Stem is in process.
Our pipeline products are the FDA approved stem cell therapies for various indications with unmet medical needs, mainly in the fields of orthopedics and wound healing.
The company has raised to date $1,125.000 from angel investors and accelerator seed funding. We are raising $4 million in equity financing to be used for device distribution in US, regulatory approval in Europe and Asia-Pacific, and stem-cell therapeutics development based on expedited FDA pathway (RMAT – Regenerative Medicine Advanced Therapy).
Tangen Biosciences, Inc.
TangenDx is a Point of Care platform with a built-in flexibility which enables it to perform up to 32 DNA/RNA diagnostic assays in a single run. TangenDx’s rapid direct-from-blood detection of blood stream infections provides an extremely high diagnostic sensitivity in less than one hour from sample to answer. Tangen has already developed TB, Candida, and Anthrax tests directly from blood.
Tangen’s Candida panel can detect five different Candida species, with the sensitivity of 1 CFU/ml, which has been validated by Rhode Island Hospital. Recently, a third party demonstrated that Tangen’s Anthrax assay can routinely detect 5 CFU/ml of Bacillus anthracis in blood. This has been repeated over 20 times and this sensitivity is over 75 times better than any other platform has been able to deliver.
In additional to the already developed tests, antimicrobial resistance panel and ESKAPE panel are being developed.
Dynamic Light, Inc.
Dynamic Light develops patented algorithm and software technology which uses the principles of dynamic light scattering to generate ‘speckle’ images which enable non-invasive, real-time, continuous, and quantitative visualization of blood flow in living tissues. Speckle imaging capability is of great current interest for health care since it enables monitoring of tissue perfusion during surgery. The best current competing technology involves the injection of a dye, Indocyanine green, into patients. A fraction of patients experience adverse reactions to the dye, and the contrast provided by the dye fades quickly, making this an undesirable, cumbersome, and costly procedure. The improved intraoperative perfusion assessment capabilities of speckle imaging have the potential to dramatically reduce the cost of complications in open brain vascular surgeries and plastic reconstructive surgery.
Paragate Medical Ltf.
Paragate’s unique Implantable Peritoneal Ultrafiltration is a minimally invasive, laparoscopically implanted device, acting as a mechanical bypass of the kidneys.
By continuously inducing controlled hydrostatic pressure gradient, systemic isotonic ﬂuids are drawn from the neighboring tissues and slowly drained to the urinary system, independently of the kidney function and thus preventing accumulation of excess fluid.
The device is wirelessly rechargeable and configurable and can be tailored per patient needs, while providing monitoring data to the treating physician/center through a dedicated patient management platform.
The device solves the major pitfalls of the current treatments, requiring acute and aggressive fluid removal or dialysis-based solutions that impose great burden on the patients and high infection risk.
D&P Bioinnovations, LLC, [D&P] is a regenerative medicine company focused on repairing damaged organs with engineered biomaterials and stem cells. The company has developed a platform absorbable immunomodulatory medical device implant to regenerate damaged organs: gastro-intestine, blood vessels, nerves, tendons/ligaments, and muscle. This platform technology can address the global regenerative medicine market that is expected to accrue over $110 billion by the mid 2020s. However, D&P’s first therapeutic indication is developing an implantable, bioresorbable medical device to regenerate a damaged esophagus (organ providing food to the stomach).
GraftWorx has created and clinically validated an end-to-end remote monitoring platform for proactive and noninvasive fluid management and arteriovenous access monitoring in hemodialysis patients. Our solution will generate $10.3 billion of value by growing revenue for dialysis providers and creating cost savings for payers. The GraftWorx system has been validated on over 130 patients across 4 clinical studies, has been granted 4 patents and has 23 patents pending, and we expect to receive FDA clearance in early 2020. We have closed a strategic partnership with WL Gore and clinical partnerships with prospective dialysis customers who manage 50,000 patients. This SmartPatch remote monitoring platform comprises a novel multi-modal sensor device in an ultra-low-power flexible package, a seamless & secure data transmission pathway, and clinical alert generation via proprietary algorithms.
Technology Value Proposition: Sonix-A8 Technology is a revolutionary new approach that combines multiple energies to activate biochemical pathway within the bacteria that kills them.
This device kills bacteria that lies on the surface and below the skin surface where traditional treatments can’t reach. Sonix-A8 is a patented technology with proven clinical efficacy to kill Propionibacterium acnes bacteria; 510K application is in process for FDA approval.
Sonix-A8 has shown early clinical efficacy for MRSA and many other gram positive and negative bacteria. The unique value proposition of this product is that Sonix-A8 can break biofilms. Microorganisms growing in a biofilm are highly resistant to antimicrobial agents (MDR) by one or more mechanisms. These microorganisms have been shown to be associated with several human diseases and colonize on wide variety of medical devices and implants. These also are of concern in Healthcare Associated Infections (HAI) and Surgical Site Infections (SSI).
Azure8 has unique opportunity to is expand the scope of this technology in medical and hospital applications and wound care.
Exact Imaging Inc.
Exact Imaging (www.exactimaging.com) is the world’s leader in high-resolution micro-ultrasound systems enabling real-time imaging and guided biopsies in the urological market for prostate cancer. Exact Imaging’s ExactVu™ micro-ultrasound platform operates at 29 MHz and enables a whole new level of resolution with the benefits of ease of use, affordability, and is an extension of the current urological workflow. Using the Exact Imaging platform, urologists are able to visualize areas of interest in the prostate and specifically target biopsies at those areas. For those cases where MRI might assist, the FusionVu™ micro-US/MRI fusion application operates on the ExactVu micro-ultrasound platform and facilitates fast, simple MRI fusion-based targeting with the guidance of the micro-ultrasound system’s 70-micron real-time resolution. The ExactVu micro-ultrasound system including the FusionVu application has received regulatory approval in the European Union (CE Mark), the United States (FDA 510(k)), and Canada (Health Canada medical device license).
Renal Sense Inc
RenalSense™ is a medical device company dedicated to real-time renal diagnostics. Renal Sense is focused on monitoring renal function in critically ill patients, in order to detect the risk of Acute Kidney Injury (AKI) and enable early intervention. This electronic monitoring replaces manual and intermittent measurements of urine output, or daily blood tests of kidney function indicators which are unreliable, or too late.
RenalSense developed Clarity RMS™ – an elegant solution that continuously and automatically monitors urine flow for real-time assessment of changes in renal function and detection of AKI risk.
This product facilitates early therapeutic intervention, as well as improved fluid management, for patients at risk of AKI.
The technology also significantly improves ICU economics by reducing the need for extended ICU stays due to AKI, dramatically lowering costs, and increasing patient turnover.
The PHANTOM™ is Aevumed’s first suture anchor that comes with three sutures and Aevumed’s proprietary MicroThread™ Technology which is a triple thread with unique micro-structure on its surface to aid in pull-out strength (265% stronger in low density bone). Aevumed is developing the PHANTOM-L™, a unique Lateral Row knotless anchor that provides superior bone fixation using Aevumed’s MicroThread™ technology and a suture retention feature. Furthermore, Aevumed is also currently developing the PHANTOM-X™, a biologic delivery system that; (1) provides adequate tendon-bone attachment; (2) reduces tendon stress; (3) provides wide attachment to reduce the current (20%-90%) retear rates. Surgeons would be able to use all three products from Aevumed, the PHANTOM® (Single Row), PHANTOM-L™ (Lateral Row), and PHANTOM-X™ (Biologic) to tackle large tears and reduce the retear rate. These products integrate well within surgeon work flow and are much easier and faster than current solutions on the market with minimum training.
PhotoniCare is building a low-cost diagnostic platform that uses light to see through tissue. The first product on this platform will fundamentally change the way physicians manage middle ear infections, the leading cause of hearing loss, antibiotic use, and surgeries in children, where the current gold standard is incorrect 50% of the time. With the TOMi Scope, physicians can now see through the eardrum to directly visualize the middle ear and determine whether antibiotic use or surgical intervention may be necessary. Diagnostic accuracy in a recent clinical study using the technology showed an accuracy of 90%+, suggesting significant improvement over the standard of care. The device is in use in multiple clinics in the U.S. and FDA clearance is expected soon. We are raising $8M to launch our first product and build out additional products on our platform in eye, dental, and consumer health markets.
Virtus Inspire Ventures
VP and Head of International Business Development